Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Corzide (Nadolol and bendroflumethiazide)

Corzide is a combination of nadolol (a non-selective beta-blocker) and bendroflumethiazide (a thiazide diuretic). It is used in the treatment of hypertension.

Corzide (Nadolol and bendroflumethiazide) Uses:

Hypertension:
- Used for management of hypertension (not for initial therapy)

Corzide (Nadolol and bendroflumethiazide) Dose in Adults

Corzide dose in the treatment of Hypertension:

Note: Not for initial therapy. Dose must be individualized.

Initial:
Nadolol 40 mg/bendroflumethiazide 5 mg OD orally
May increase to nadolol 80 mg/bendroflumethiazide 5 mg OD orally based on patient response.

Corzide (Nadolol and bendroflumethiazide) Dose in Childrens

Not recommended for use in children.

Pregnancy Risk Factor C

This combination has not been used in animal reproduction studies.
Talk to individual agents.

Corzide use during breastfeeding:

Breast milk contains bendroflumethiazide and naprolol.
According to the manufacturer breast-feeding during therapy should be considered in light of the risks to the infant as well as the benefits to the mother. Refer to individual agents.

Corzide Dose in Kidney Disease:

CrCl >50 mL/minute/1.73 m²:
- Administer dose q 24 hours
CrCl 31 to 50 mL/minute/1.73 m²:
- Administer dose q 24 to 36 hours
CrCl 10 to 30 mL/minute/1.73 m²:
- Administer dose q 24 to 48 hours
CrCl <10 mL/minute/1.73 m²:
- Administer dose q 40 to 60 hours

Corzide Dose in Liver disease:

The manufacturer's labelling does not mention dosage modifications.
Use with caution since changes to the electrolyte and fluid balance can lead to hepatic coma.

Side Effects of Corzide (Nadolol and bendroflumethiazide)

See individual agents (Nadolol and bendroflumethiazide)

Contraindications to Corzide (Nadolol and bendroflumethiazide):

Hypersensitivity to bendroflumethiazide, drugs derived from sulfonamides, or any other component of the formulation
Bronchial asthma
Sinus bradycardia
Heart block of greater than the first degree is possible (except for patients who have a working artificial pacemaker).
Cardiogenic shock
Uncompensated cardiac Failure
Anuria

Notification:

Although the FDA-approved product labelling warns that this medication should not be taken with other groups of drugs that contain sulfonamides, the scientific validity of this claim has been questioned.
For more information, go to "Warnings/Precautions."

Warnings/Precautions

Anaphylactic reactions
- Avoid using this product if you have had severe allergic reactions to allergens in the past.
- Beta-blockers can make patients more sensitive to repeated challenges.
- Patients taking beta-blockers might experience anaphylaxis (e.g., epinephrine), which can be ineffective or cause undesirable side effects.
Electrolyte disturbances:
- Thiazides can cause hypokalemia, hypochloremic acidkalosis, hypomagnesemia and hyponatremia.
- Correct electrolyte disturbances as appropriate before initiating.
Photosensitivity
- Photosensitization can occur.
Allergy to sulfonamide ("sulfa")
- Wide-ranging contraindications for patients who have previously experienced an adverse reaction to sulfonamides are listed on FDA-approved product labels for drugs that contain sulfonamide chemical groups.
- Cross-reactivity between members of a class is conceivable (eg two antibiotic sulfonamides).
- Concerns about cross-reactivity have been expressed for all substances with the sulfonamide structure.
- A fuller understanding of allergic pathways shows that it may not be possible for non-antibiotic or antibiotic sulfonamides to cross-react with each other.
- Sulfonamides that are not antibiotics are not likely to trigger mechanisms of cross-reaction from antibody formation or anaphylaxis (anaphylaxis).
- Less is known about type IV T-cell reactions, such as maculopapular skin rash. Based on what is known at the moment, it is difficult to rule out this possibility.
- Some clinicians opt to avoid these classes in cases of severe reactions (Stevens Johnson syndrome/TEN).
Bronchospastic disease
- Patients with bronchospastic diseases should not be given beta-blockers.
- If you do use it, please be careful and keep an eye on it.
Conductive abnormality
- Be mindful of any existing disorders, such as sick sinus syndrome, before beginning nadolol.
Diabetes:
- Patients with DM should be cautious
- Hypoglycemia may be potentiated and/or mask symptoms (eg diaphoresis and tachycardia).
- Also, may reduce insulin secretion when hyperglycemia occurs
- It may be necessary to adjust anti-diabetic medications.
Gout
- In some people with a history of gout or who are at risk for chronic renal failure, thiazide diuretics can cause gout.
Heart failure (HF):
- Patients with compensated heart disease should be cautious and monitored for any possible complications. Noradrolol's efficacy in HF has not yet been proven to work.
Hepatic impairment
- Patients with impaired liver function or progressive liver disease should be cautious.
- Thiazides can alter fluid and electrolyte equilibrium, which could lead to hepatic coma.
Hypercalcemia:
- Thiazides could decrease renal calcium excretion
- Patients with hypercalcemia should be advised to stop using it.
Hypercholesterolemia:
- Patients with high or moderate cholesterol should be cautious
- Thiazides have been linked to an increase in cholesterol and triglyceride.
Myasthenia gravis:
- Patients with myasthenia gravis should be treated with caution.
Parathyroid disease
- Thiazide diuretics reduce calcium excretion.
- Long-term use has been associated with pathologic changes in parathyroid glands, including hypophosphatemia and hypercalcemia.
- Do not discontinue testing for parathyroid function.
Raynaud and peripheral vascular disease (PVD).
- It can cause or exacerbate arterial insufficiency symptoms in patients with Raynaud and PVD.
- Be cautious and monitor for arterial obstruction.
Untreated Pheochromocytoma
- Before any beta-blocker can be used, it is necessary to have adequate alpha-blockade.
Psoriasis:
- Although beta-blocker usage has been linked to psoriasis exacerbation or induction, cause and effect are not clear.
Renal impairment
- Patients with impaired renal function should be cautious
- Dosage adjustments may be required.
- Stop using if you have progressive renal impairment
- Patients with impaired renal function may experience cumulative effects, including azotemia.
- Patients with chronic kidney disease could be at greater risk of developing acute renal failure due to thiazides.
- Patients with anuria are not advised to use this product.
Systemic lupus erythematosus (SLE):
- SLE activation or exacerbation may occur.
Thyroid disease:
- Hyperthyroidism may be disguised (eg, Tachycardia).
- Thyrotoxicosis should be treated and monitored if it is suspected.
- Rapid withdrawal can worsen hyperthyroidism symptoms or cause a thyroid storm.

Nadolol and bendroflumethiazide: Drug Interaction

Risk Factor C (Monitor therapy)
Acetylcholinesterase Inhibitors	May enhance the bradycardic effect of Beta-Blockers.
Ajmaline	Sulfonamides might make ajmaline more harmful or poisonous. In particular, there may be an elevated risk for cholestasis.
Alcohol (Ethyl)	Increases the effectiveness of thiazide and thiazide-like diuretics in lowering orthostatic blood pressure.
Alfuzosin	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Allopurinol	The possibility of allergic or hypersensitive reactions to allopurinol may be increased by thiazide and thiazide-like diuretics. The serum concentration of Allopurinol may rise in response to thiazides and thiazide-like diuretics. In particular, Thiazide Diuretics may raise Oxypurinol's levels, an active metabolite of Allopurinol.
Alpha1-Blockers	Alpha1Blockers' orthostatic hypotensive action may be strengthened by beta-blockers. Ophthalmic products likely carry a lower level of risk than systemic ones.
Aminolevulinic Acid (Topical)	Aminolevulinic Acid's photosensitizing impact may be enhanced by photosensitizing agents (Topical).
Amiodarone	May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.
Amphetamines	May diminish the antihypertensive effect of Antihypertensive Agents.
Angiotensin-Converting Enzyme Inhibitors	Angiotensin-Converting Enzyme Inhibitors' hypotensive effects may be enhanced by thiazide and thiazide-like diuretics. Angiotensin-Converting Enzyme Inhibitors' nephrotoxic effects may be increased by thiazide and thiazide-like diuretics.
Anticholinergic Agents	May raise the levels of thiazide and thiazide-like diuretics in the blood.
Antidiabetic Agents	The therapeutic value of anti-diabetic agents may be diminished by thiazide and thiazide-like diuretics.
Antidiabetic Agents	The therapeutic benefit of anti-diabetic agents may be reduced by hyperglycemia-associated agents.
Antipsychotic Agents (Second Generation [Atypical	Antipsychotic drugs' hypotensive effects may be enhanced by blood pressure-lowering medications (Second Generation [Atypical]).
Barbiturates	Increases the effectiveness of thiazide and thiazide-like diuretics in lowering orthostatic blood pressure.
Barbiturates	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Benperidol	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Bradycardia-Causing Agents	May enhance the bradycardic effect of other Bradycardia-Causing Agents.
Bretylium	May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.
Brigatinib	May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.
Brimonidine (Topical	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Bupivacaine	Beta-Blockers may increase the serum concentration of Bupivacaine.
Calcium Channel Blockers (Nondihydropyridine)	May enhance the hypotensive effect of BetaBlockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers. Exceptions: Bepridil.
Calcium Salts	The excretion of calcium salts may be decreased by thiazide and thiazide-like diuretics. Metabolic alkalosis can also be brought on by continued concurrent usage.
CarBAMazepine	Thiazide and Thiazide-Like Diuretics may intensify CarBAMazepine's negative/toxic effects. Particularly, there could be a higher risk of hyponatremia.
Cardiac Glycosides	Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.
Cardiac Glycosides	Cardiac Glycosides may have an increased negative or toxic effect when used with thiazide and thiazide-Like Diuretics. Particularly, the hypokalemic and hypomagnesemic impact of thiazide diuretics may worsen cardiac glycoside toxicity.
Cholinergic Agonists	Beta-Blockers may make Cholinergic Agonists' harmful or toxic effects worse. The possibilities for bronchoconstriction and aberrant cardiac conduction are of special concern. Management: Use cautious while combining these drugs, and keep an eye out for conduction issues. Because methacholine may cause further bronchoconstriction when used with any beta blocker, avoid using it.
Corticosteroids (Orally Inhaled)	Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact.
Corticosteroids (Systemic)	Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact.
Cyclophosphamide	Thiazide and Thiazide-Like Diuretics may intensify Cyclophosphamide's harmful or hazardous effects. Particularly, granulocytopenia could be worsened.
Dexketoprofen	Sulfonamides' harmful or poisonous effects could be amplified.
Dexmethylphenidate	Can lessen an antihypertensive drug's therapeutic impact.
Diacerein	Could make diuretics' therapeutic effects stronger. Particularly, there may be a higher chance of hypokalemia or dehydration.
Diazoxide	Thiazide and Thiazide-Like Diuretics may intensify Diazoxide's harmful or toxic effects.
Diazoxide	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Dipyridamole	Could make beta-blockers' bradycardic impact stronger.
Disopyramide	Could make beta-blockers' bradycardic impact stronger. Beta-blockers might make Disopyramide's adverse inotropic impact worse.
DULoxetine	The hypotensive impact of DULoxetine may be enhanced by blood pressure lowering medications.
EPINEPHrine (Nasal)	The hypertensive impact of EPINEPHRINE may be enhanced by beta-blockers like Nonselective (Nasal).
EPINEPHrine (Oral Inhalation)	The hypertensive impact of EPINEPHRINE may be enhanced by beta-blockers like Nonselective (Oral Inhalation).
Epinephrine (Racemic)	Epinephrine's hypertensive action may be enhanced by beta-blockers like Nonselective (Racemic).
EPINEPHrine (Systemic)	The hypertensive impact of EPINEPHRINE may be enhanced by beta-blockers like Nonselective (Systemic).
Erdafitinib	P-glycoprotein/ABCB1 Substrates serum levels can rise.
Herbs (Hypertensive Properties)	May diminish the antihypertensive effect of Antihypertensive Agents.
Herbs (Hypotensive Properties)	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Hypotension-Associated Agents	Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents.
Insulins	Beta-Blockers may enhance the hypoglycemic effect of Insulins.
Ipragliflozin	The toxic and harmful effects of thiazide and thiazide-like diuretics may be increased. In particular, there may be an elevated risk for intravascular volume depletion.
Ivabradine	The arrhythmogenic impact of ivabradine may be enhanced by thiazide and thiazide-like diuretics.
Ivabradine	Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine.
Lacosamide	Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.
Levodopa-Containing Products	Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Containing Products.
Licorice	The arrhythmogenic impact of ivabradine may be enhanced by thiazide and thiazide-like diuretics.
Lidocaine (Systemic)	Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact.
Lidocaine (Topical)	Beta-blockers might boost the level of lidocaine in the blood (Systemic).
Lormetazepam	Beta-blockers might boost the level of lidocaine in the blood (Topical).
Lumacaftor	May lower the level of P-glycoprotein/ABCB1 Substrates in the serum. The serum concentration of P-glycoprotein/ABCB1 Substrates may rise when using lumacaftor.
Mepivacaine	Mepivacaine's serum levels may rise after taking beta-blockers.
Methoxyflurane	May enhance the hypotensive effect of Beta-Blockers.
Methylphenidate	May diminish the antihypertensive effect of Antihypertensive Agents.
Midodrine	May enhance the bradycardic effect of Bradycardia-Causing Agents.
Molsidomine	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Multivitamins/Fluoride (with ADE)	May intensify the effects of thiazide and thiazide-like diuretics on hypercalcemia.
Multivitamins/Minerals (with ADEK, Folate, Iron)	The effect of multivitamins and minerals on hypercalcemia may be enhanced by thiazide and thiazide-like diuretics (with ADEK, Folate, Iron).
Multivitamins/Minerals (with AE, No Iron)	The serum concentration of multiple vitamins and minerals may rise after taking thiazide and thiazide-like diuretics (with AE, No Iron). Particularly, thiazide diuretics may reduce calcium excretion, and long-term concurrent usage may result in metabolic alkalosis.
Naftopidil	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Neuromuscular-Blocking Agents (Nondepolarizing)	The neuromuscular-blocking action of neuromuscular-blocking agents may be enhanced by thiazide and thiazide-like diuretics (Nondepolarizing).
Nicergoline	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Nicorandil	The hypotensive effects of blood pressure-lowering medications may be strengthened.
NIFEdipine	May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.
Nitroprusside	Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside.
Nonsteroidal Anti-Inflammatory Agents	May diminish the antihypertensive effect of BetaBlockers.
Nonsteroidal Anti-Inflammatory Agents	Nonsteroidal Anti-Inflammatory Agents' nephrotoxic effects may be intensified by thiazide and thiazide-like diuretics. Thiazide and Thiazide-Like Diuretics may have less of a therapeutic impact when used with nonsteroidal anti-inflammatory drugs.
Opioid Agonists	Could make diuretics' harmful or toxic effects worse. Opioid antagonists may reduce diuretics' therapeutic benefit.
Opioids (Anilidopiperidine	May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.
Oxcarbazepine	Thiazide and Thiazide-Like Diuretics may intensify OXcarbazepine's negative/toxic effects. Particularly, there could be a higher risk of hyponatremia.
Pentoxifylline	The hypotensive effects of blood pressure-lowering medications may be strengthened.
P-glycoprotein/ABCB1 Inducers	May lower the level of Pglycoprotein/ABCB1 Substrates in the serum. P-glycoprotein inducers may also further restrict the distribution of p-glycoprotein substrates to particular cells, tissues, and organs that have high levels of p-glycoprotein (e.g., brain, T-lymphocytes, testes, etc.).
P-glycoprotein/ABCB1 Inhibitors	Pglycoprotein/ABCB1 Substrates serum levels can rise. Additionally, p-glycoprotein inhibitors may improve the distribution of pglycoprotein substrates to particular cells, tissues, and organs where high levels of p-glycoprotein are present (e.g., brain, T-lymphocytes, testes, etc.).
Pholcodine	Pholcodine's hypotensive impact may be strengthened by blood pressure lowering medications.
Phosphodiesterase 5 Inhibitors	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Porfimer	The photosensitizing effect of Porfimer may be strengthened by photosensitizing agents.
Prostacyclin Analogues	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Quinagolide	The hypotensive effects of blood pressure-lowering medications may be strengthened.
Ranolazine	P-glycoprotein/ABCB1 Substrates serum levels can rise.
Reboxetine	Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact.
Regorafenib	Could make beta-blockers' bradycardic impact stronger.
Reserpine	May strengthen beta-blockers' hypotensive effects.
Ruxolitinib	Bradycardia-Causing Agents' bradycardic effect might be enhanced. Management: The Canadian product labelling for roxolitinib advises against using it in conjunction with medications that can cause bradycardia whenever feasible.
Selective Serotonin Reuptake Inhibitors	The hyponatremic effects of thiazide and thiazide-like diuretics may be enhanced.
Sulfonylureas	Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.
Terlipressin	May enhance the bradycardic effect of Bradycardia-Causing Agents.
Tofacitinib	May enhance the bradycardic effect of Bradycardia-Causing Agents.
Toremifene	Toremifene's hypercalcemic impact may be enhanced by thiazide and thiazide-like diuretics.
Verteporfin	Verteporfin's photosensitizing effect may be strengthened by photosensitizing agents.
Vitamin D Analogs	The hypercalcemic impact of vitamin D analogues may be enhanced by thiazides and thiazide-like diuretics.
Yohimbine	May diminish the antihypertensive effect of Antihypertensive Agents.
Risk Factor D (Consider therapy modification)
Alpha2-Agonists	May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable. Exceptions: Apraclonidine.
Amifostine	Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.
Bile Acid Sequestrants	The absorption of thiazide and thiazide-like diuretics may be reduced. Also reduced is the diuretic reaction.
Ceritinib	Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib. Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy. Exceptions are discussed in separate monographs.
Dofetilide	The QTc-prolonging action of dofetilide may be enhanced by thiazide and thiazide-like diuretics. The blood concentration of Dofetilide may rise in response to thiazide and thiazide-like diuretics. Management: Despite the fact that hydrochlorothiazide is clearly listed as being contraindicated, the risk certainly applies to all thiazide and thiazide-like diuretics and may even be larger when using chlorthalidone or bendroflumethiazide. When feasible, take into account alternatives.
Dronedarone	May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in betablocker dose.
Ergot Derivatives	Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. Exceptions: Nicergoline.
Fingolimod	Beta-Blockers may enhance the bradycardic effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia.
Grass Pollen Allergen Extract (5 Grass Extract)	Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine. Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.
Green Tea	May decrease the serum concentration of Nadolol. Management: Advise patients to minimize green tea consumption during nadolol treatment. The impact of separating nadolol doses from green tea consumption has not been investigated.
Lithium	The excretion of lithium may be reduced by thiazide and thiazide-like diuretics.
Obinutuzumab	May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.
Siponimod	Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod. Management: Avoid coadministration of siponimod with drugs that may cause bradycardia.
Sodium Phosphates	Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.
Theophylline Derivatives	Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.
Topiramate	The hypokalemic impact of topiramate may be enhanced by thiazide and thiazide-like diuretics. The blood concentration of topiramate may rise in response to thiazide and thiazide-like diuretics. When using a thiazide diuretic, monitor for elevated topiramate levels and any negative consequences (such as hypokalemia). Serum potassium levels should be closely watched when receiving concurrent treatment. There may be a need to lower topiramate dosage.
Risk Factor X (Avoid combination)
Aminolevulinic Acid (Systemic)	Aminolevulinic Acid's photosensitizing impact may be enhanced by photosensitizing agents (Systemic).
Beta2-Agonists	Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2Agonists.
Bromperidol	Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents.
Floctafenine	May enhance the adverse/toxic effect of Beta-Blockers.
Levosulpiride	Thiazide and Thiazide-Like Diuretics may intensify Levosulpiride's negative/toxic effects.
Mecamylamine	Sulfonamides may intensify Mecamylamine's harmful or hazardous effects.
Methacholine	Beta-Blockers might make methacholine's harmful or toxic effects worse.
Promazine	Promazine's ability to prolong QTc may be enhanced by thiazide and thiazide-like diuretics.
Rivastigmine	Could make beta-blockers' bradycardic impact stronger.

Monitoring parameters:

Blood pressure
Heart rate
Fluid and electrolyte balance
Serum glucose regularly (in patients with diabetes)
Renal function

How to administer Corzide (Nadolol and bendroflumethiazide)?

P/O

Administer without regard to meals.

Mechanism of action of Corzide (Nadolol and bendroflumethiazide):

Nadolol is a competitive inhibitor of beta1- and Beta2-adrenergic stimulation.
Bendroflumethiazide prevents sodium from being reabsorbed in the distal tubules, leading to an increase in sodium, water, potassium, and hydrogen ion excretion.

Also, see individual agents.

Bioavailability:

Bendroflumethiazide: When used in this combination, bioavailability is increased 30% compared to single-agent administration.

International Brands of Nadolol and bendroflumethiazide:

Corzide
Corgaretic
Corgaretic-40
Corgaretic-80

Nadolol and bendroflumethiazide Brand Names in Pakistan

No Brands Available in Pakistan.

Corzide (Nadolol and bendroflumethiazide)

Corzide (Nadolol and bendroflumethiazide) Uses:

Hypertension:

Corzide (Nadolol and bendroflumethiazide) Dose in Adults

Corzide dose in the treatment of Hypertension:

Corzide (Nadolol and bendroflumethiazide) Dose in Childrens

Pregnancy Risk Factor C

Corzide use during breastfeeding:

Corzide Dose in Kidney Disease:

Corzide Dose in Liver disease:

Side Effects of Corzide (Nadolol and bendroflumethiazide)

Contraindications to Corzide (Nadolol and bendroflumethiazide):

Warnings/Precautions

Anaphylactic reactions

Electrolyte disturbances:

Photosensitivity

Allergy to sulfonamide ("sulfa")

Bronchospastic disease

Conductive abnormality

Diabetes:

Gout

Heart failure (HF):

Hepatic impairment

Hypercalcemia:

Hypercholesterolemia:

Myasthenia gravis:

Parathyroid disease

Raynaud and peripheral vascular disease (PVD).

Untreated Pheochromocytoma

Psoriasis:

Renal impairment

Systemic lupus erythematosus (SLE):

Thyroid disease:

Monitoring parameters:

How to administer Corzide (Nadolol and bendroflumethiazide)?

Mechanism of action of Corzide (Nadolol and bendroflumethiazide):

International Brands of Nadolol and bendroflumethiazide:

Nadolol and bendroflumethiazide Brand Names in Pakistan

Recent Posts

Related Posts